The clinical spectrum of Castleman's disease

Angela Dispenzieri, James O. Armitage, Matt J. Loe, Susan M. Geyer, Jake Allred, John K. Camoriano, David M. Menke, Dennis D. Weisenburger, Kay Ristow, Ahmet Dogan, Thomas M. Habermann

Research output: Contribution to journalArticlepeer-review

133 Scopus citations


Castleman's disease (CD) is a rare, poorly understood lymphoproliferative disease. The spectrum of symptoms and course of disease are broad, but there is no large study describing the natural history of this disease. Basic clinic and laboratory data from the records of 113 patients with CD evaluated at the Mayo Clinic and University of Nebraska were abstracted. The impact of these variables on overall survival (OS) from time of diagnosis was evaluated. Sixty patients had multicentric disease. Of the patients with multicentric CD, 32% had criteria sufficient for a diagnosis of POEMS syndrome. For all patients, 2, 5, and 10-year OS was 92%, 76%, 59%, respectively. Most of the factors identified as risk factors for death on univariate analysis cosegregated with diagnostic criteria for POEMS syndrome, which supported the concept of four categories of CD, which are (along with their 5-year OS): (1) unicentric CD (91%); (2) multicentric CD associated with the osteosclerotic variant of POEMS syndrome (90%); (3); multicentric CD without POEMS syndrome (65%); and (4) multicentric CD with POEMS syndrome without osteosclerotic lesions (27%). We have demonstrated that CD represents a spectrum of disease that can be differentiated by simple prognostic factors that provide a framework for further study.

Original languageEnglish (US)
Pages (from-to)997-1002
Number of pages6
JournalAmerican journal of hematology
Issue number11
StatePublished - Nov 2012

ASJC Scopus subject areas

  • Hematology


Dive into the research topics of 'The clinical spectrum of Castleman's disease'. Together they form a unique fingerprint.

Cite this